Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
7.87
+0.32 (4.24%)
At close: Nov 7, 2025, 4:00 PM EST
7.66
-0.21 (-2.67%)
After-hours: Nov 7, 2025, 4:21 PM EST
Cartesian Therapeutics Revenue
Cartesian Therapeutics had revenue of $452.00K in the quarter ending September 30, 2025, with 16.80% growth. This brings the company's revenue in the last twelve months to $1.09M, down -97.72% year-over-year. In the year 2024, Cartesian Therapeutics had annual revenue of $38.91M with 49.64% growth.
Revenue (ttm)
$1.09M
Revenue Growth
-97.72%
P/S Ratio
186.44
Revenue / Employee
$16,530
Employees
66
Market Cap
204.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38.91M | 12.91M | 49.64% |
| Dec 31, 2023 | 26.00M | -84.77M | -76.53% |
| Dec 31, 2022 | 110.78M | 25.70M | 30.21% |
| Dec 31, 2021 | 85.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRNAC News
- 9 days ago - Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewsWire
- 5 weeks ago - Cartesian Therapeutics Announces New Employment Inducement Grant - GlobeNewsWire
- 2 months ago - Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Cartesian Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 months ago - Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis - GlobeNewsWire
- 6 months ago - Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewsWire
- 7 months ago - Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire